12 Month Price Forecast For CNTA
Distance to CNTA Price Forecasts
CNTA Price Momentum
🤔 Considering Centessa (CNTA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 2:49 AM UTC
CNTA Analyst Ratings & Price Targets
Based on our analysis of 12 Wall Street analysts, CNTA has a consensus that is bullish. The median price target is $27.00, with forecasts ranging from $24.00 to $35.00. Currently, there are 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CNTA currently trading at $16.68, the median price forecast suggests a 61.9% upside. The most optimistic forecast comes from Kostas Biliouris at BMO Capital, projecting a 109.8% upside, while Debjit Chattopadhyay at Guggenheim provides the most conservative target, suggesting a 43.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNTA Analyst Consensus
CNTA Price Target Range
Latest CNTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 7, 2025 | TD Cowen | Stacy Ku | Buy | Initiates | $0.00 |
| Nov 15, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $28.00 |
| Sep 19, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Initiates | $33.00 |
| Sep 19, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Upgrade | $26.00 |
| Sep 16, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $35.00 |
| Sep 11, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $24.00 |
| Sep 11, 2024 | Jefferies | Kelly Shi | Buy | Maintains | $19.00 |
| Sep 9, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $20.00 |
| Aug 14, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $14.00 |
| Jul 18, 2024 | Oppenheimer | Francois Brisebois | Outperform | Initiates | $14.00 |
| Jun 21, 2024 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $11.00 |
| Apr 1, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $15.00 |
| Nov 15, 2023 | Jefferies | Kelly Shi | Buy | Upgrade | $11.00 |
| Oct 26, 2023 | Morgan Stanley | Matthew Harrison | Equal-Weight | Upgrade | $8.00 |
| Aug 15, 2023 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $5.00 |
| Aug 15, 2023 | SVB Securities | David Risinger | Outperform | Maintains | $11.00 |
| Aug 15, 2023 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $10.00 |
| Jul 25, 2023 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $15.00 |
| Jun 21, 2023 | Evercore ISI Group | Umer Raffat | Outperform | Initiates | $0.00 |
| Jun 12, 2023 | Guggenheim | Buy | Initiates | $0.00 |
Stocks Similar to Centessa Pharmaceuticals Limited
The following stocks are similar to Centessa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Centessa Pharmaceuticals Limited (CNTA) Financial Data
Centessa Pharmaceuticals Limited has a market capitalization of $2.00B with a P/E ratio of -10.5x. The company generates $6.85M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -2,358.9% and return on equity of -42.5%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Centessa Pharmaceuticals Limited (CNTA) Company Overview
About Centessa Pharmaceuticals Limited
Develops medicines for various health conditions.
Centessa Pharmaceuticals operates as a clinical-stage pharmaceutical company, focusing on the discovery and development of innovative treatments for patients. The company generates revenue through the advancement of its drug pipeline, which includes specialized therapies targeting hemophilia, sleep disorders, and solid tumors, primarily through collaborations, partnerships, and eventually product sales upon successful commercialization.
Founded in 2020 and headquartered in Altrincham, UK, Centessa Pharmaceuticals is actively engaged in developing a range of advanced therapeutic candidates, including both clinical and preclinical assets. Their diverse pipeline reflects a strategic emphasis on unmet medical needs, which positions the company for potential growth in the pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
76
CEO
Dr. Saurabh Saha M.D., Ph.D.
Country
United Kingdom
IPO Year
2021
Website
www.centessa.comCentessa Pharmaceuticals Limited (CNTA) Latest News & Analysis
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
14 days agoCentessa Pharmaceuticals appointed Dr. Stephen Kanes as Chief Medical Officer. He brings over 30 years of experience in neuroscience and drug development.
The appointment of a seasoned CMO like Dr. Kanes can enhance Centessa's drug development capabilities, potentially increasing investor confidence and impacting stock performance.
Centessa Pharmaceuticals has halted its SerpinPC candidate for Hemophilia B, achieving $200 million in savings. Positive phase 1 results for ORX750 were reported, with phase 2a results anticipated in 2025.
Centessa's decision to shelve SerpinPC reduces costs by $200 million, enhancing financial stability. Positive results for ORX750 indicate potential growth and future value in sleep disorder treatments.
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
2 months agoCentessa Pharmaceuticals (Nasdaq: CNTA) reported its Q3 2024 financial results and provided a business update on November 12, 2024.
Centessa Pharmaceuticals' Q3 financial results and business update indicate its progress and potential in the pharmaceutical sector, influencing investor confidence and stock performance.
Centessa Pharmaceuticals (NASDAQ: CNTA) has nearly doubled in value this year, with Morgan Stanley significantly raising its price target, suggesting potential for continued growth.
Centessa Pharmaceuticals' stock surge and Morgan Stanley's increased price target signal strong market confidence, potentially attracting more investors and driving further price appreciation.
ORX142 shows promise as a novel drug candidate for treating excessive daytime sleepiness in certain neurological and psychiatric disorders, based on recent non-human primate data.
The positive NHP data for ORX142 suggests potential market growth in the EDS treatment sector, indicating possible revenue increases for the developing company and impacting stock valuations.
Centessa's stock surged following positive test results for a potential blockbuster narcolepsy treatment, according to an analyst's report.
Positive test results for Centessa's narcolepsy treatment could lead to significant revenue growth, increasing the stock's value and attracting investor interest in the biotech sector.
Frequently Asked Questions About CNTA Stock
What is Centessa Pharmaceuticals Limited's (CNTA) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Centessa Pharmaceuticals Limited (CNTA) has a median price target of $27.00. The highest price target is $35.00 and the lowest is $24.00.
Is CNTA stock a good investment in 2025?
According to current analyst ratings, CNTA has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CNTA stock?
Wall Street analysts predict CNTA stock could reach $27.00 in the next 12 months. This represents a 61.9% increase from the current price of $16.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Centessa Pharmaceuticals Limited's business model?
Centessa Pharmaceuticals operates as a clinical-stage pharmaceutical company, focusing on the discovery and development of innovative treatments for patients. The company generates revenue through the advancement of its drug pipeline, which includes specialized therapies targeting hemophilia, sleep disorders, and solid tumors, primarily through collaborations, partnerships, and eventually product sales upon successful commercialization.
What is the highest forecasted price for CNTA Centessa Pharmaceuticals Limited?
The highest price target for CNTA is $35.00 from Kostas Biliouris at BMO Capital, which represents a 109.8% increase from the current price of $16.68.
What is the lowest forecasted price for CNTA Centessa Pharmaceuticals Limited?
The lowest price target for CNTA is $24.00 from Debjit Chattopadhyay at Guggenheim, which represents a 43.9% increase from the current price of $16.68.
What is the overall CNTA consensus from analysts for Centessa Pharmaceuticals Limited?
The overall analyst consensus for CNTA is bullish. Out of 12 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are CNTA stock price projections?
Stock price projections, including those for Centessa Pharmaceuticals Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
